QPPV.COM KNOWLEDGE ASSESSMENT

Glofitamab: Classification, Mechanism, Safety and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Glofitamab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which set of variables would be most important when reviewing a suspected CRS case for both individual causality and aggregate signal detection?

Dose number, cycle, onset timing, tumour burden, clinical phenotype, infection evaluation, and treatment administered Only patient age and sex Only the final outcome and hospital name Only the presence or absence of a product complaint

Question 2 of 10 Which sequence best reflects a useful initial structure for reviewing a glofitamab safety case?

Start with the suspected adverse event, then ignore treatment chronology Reconstruct pretreatment, step-up and full-dose sequence, premedication, and concomitant therapy before interpreting event chronology Start with product batch information and omit disease burden Assess only the outcome because timing is not clinically informative

Question 3 of 10 A case report documents CRS after the first full treatment dose but omits the preceding step-up doses and pretreatment date. What is the main pharmacovigilance consequence?

The case cannot be medically reviewed because CRS is never assessable after a full dose The missing information prevents adequate reconstruction of the immune-activation context and dose-related timing The event should automatically be reclassified as infection The omission has no relevance because all doses have equivalent biological meaning

Question 4 of 10 What is the principal rationale for anti-CD20 pretreatment before the first glofitamab dose?

To increase the number of circulating target B cells To reduce B-cell target burden and attenuate the magnitude of initial immune activation To replace the need for step-up dosing To prevent all later infections caused by B-cell depletion

Question 5 of 10 Why should infection reports in glofitamab-treated patients include baseline immune status and previous treatment history?

Infection risk may reflect B-cell depletion, prior therapies, neutropenia, impaired humoral immunity, and active disease rather than glofitamab alone Previous treatment history is relevant only to product complaints Baseline immune status determines whether CD20 is expressed Infection causality can be established from immunoglobulin levels alone

Question 6 of 10 Which comparison between glofitamab and a conventional anti-CD20 antibody is most accurate?

Glofitamab's defining feature is direct T-cell redirection, not merely B-cell depletion Glofitamab has no activity involving normal B cells Conventional anti-CD20 antibodies always cause greater cytokine release than T-cell engagers Glofitamab acts without requiring interaction with CD3

Question 7 of 10 A patient develops confusion and somnolence after glofitamab. Which additional information is most valuable for distinguishing ICANS from alternative explanations?

Only the patient's lymphoma histology Mental-status or ICE assessment, seizure evaluation, imaging or EEG where relevant, and metabolic or infectious work-up Only the product batch number Only the date of the patient's original diagnosis

Question 8 of 10 What is the most appropriate implication of glofitamab's fixed-duration treatment context for pharmacovigilance?

All late events should be assumed to be unrelated because treatment is finite Cumulative exposure, timing of late events, and persistence of immune effects should be interpreted against the planned treatment course Only events during the first infusion are relevant Fixed duration eliminates the need to document dose number

Question 9 of 10 Which laboratory pattern is most consistent with tumour lysis syndrome after rapid tumour killing?

Low uric acid, low potassium, and isolated thrombocytosis Hyperuricaemia, hyperkalaemia, hyperphosphataemia, hypocalcaemia, and possible acute kidney injury Isolated elevation of immunoglobulins without renal changes Persistent hypophosphataemia with no other abnormalities

Question 10 of 10 Which case feature would most strongly support a diagnosis of CRS rather than an isolated fever of uncertain cause?

Fever occurring with hypotension or hypoxia soon after a step-up dose Fever occurring several months after treatment completion with no other findings Fever accompanied only by chronic anaemia Fever documented without treatment chronology or clinical assessment

Glofitamab: Classification, Mechanism, Safety and Pharmacovigilance Assessment

Cookie Settings